Please login to the form below
High Cost Drugs
This page shows the latest High Cost Drugs news and features for those working in and with pharma, biotech and healthcare.
The Holy Grail of healthcare pricing
Oh, and there’s one other small thing: by virtue of this legislation, the federal government is now required to negotiate prices for some high-cost drugs covered under Medicare. ... Presumably, the drugs that cost the system the most. Or the drugs that
Latest news
-
UK government allocates up to £680m a year to two funds offering cutting-edge treatments
for Health and Care Excellence (NICE), that balances the weights of cost versus the benefit of drugs used by the NHS. ... Scotland has already established a similar fund for innovative treatments, ‘The New Medicines Fund’, and Wales has a ‘New
-
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US
The draft guidance would allow states in the US to import prescription drugs from Canada, as part of cost-saving efforts to combat increasing drug prices in the country. ... The Democrats have also launched their own plans to tackle high drug prices,
-
Biologic patent exclusivity scrapped in new US trade deal
In the past, the US has pushed to have its exclusivity rules applied to trading partners – in the US, new drugs are afforded 12 years exclusivity for biologics. ... The Democrats also launched their own plans to tackle high drug prices in the US, which
-
Labour party plans to abolish NHS prescription charges
This in turn, reduces the overall cost to the NHS in England,” she added. ... Under the proposed plan, the federal government would gain the ability to negotiate and cap prices on certain high-cost drugs.
-
Democrats’ final pricing plan announced, 250 drugs targeted
According to the document, the maximum negotiated price for the 250 high-cost drugs must be no more than 1.2 the average price levied in six index countries – this includes ... This has remained in the final published plan, and means that the federal
More from news
Approximately 0 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Risks, reforms and rewards: the evolving Russian healthcare market
Everyone needs treatment from good doctors, preferably close to where they live, as well as inexpensive and high-quality medicine, but not counterfeit medicine and, of course, regular medical examinations. ... State spending on pharmaceuticals, which
-
Happy 70th birthday NHS: the next 70 need to be very different
However, the increased budget squeeze in England, combined with a wave of new highly-specialised and high-cost drugs is also inevitably causing conflict. ... Perhaps most significant of all is how the government intends to tackle the rising cost of
-
The NHS and ABPI at 70: inching closer to the triple win
Stevens said he believed there was still a need for an overarching UK pricing agreement, such as the PPRS, but NHS England’s role as the gatekeeper for new drugs - especially ... the high cost, specialist medicines emerging from pipelines - is here to
-
Choosing wisely
Moreover, where budgets are expanding, it's to cover the cost of essential care rather than pay for high-cost innovative drugs.”. ... Mark. “In China, richer regions are spending more and reimbursing some of the new cancer drugs.
-
Seismic shifts: Hepatitis C and payers
Prof Boxall's prediction never left my psyche and it's brought to mind whenever difficult decisions about investing public money in high-cost drugs have to be made. ... A European high cost drugs procurement strategy? The threat of an EU-wide procurement
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
How does the government plan to reshape the NHS?
This could help back up clinical trial results and inform industry’s value propositions, particularly around high cost drugs.
-
Integrated NHS finances: what do they mean for High Cost Drugs?
The CCG will still account for the use of High Cost Drugs, usually via Blueteq. ... For these services, most High Cost Drugs will still be contracted via NHS England.
-
How can pharma engage with Accountable Care Systems?
medications. If pharma extended this type of monitoring to high cost drugs, especially those that are delivered to patients’ homes and require refrigeration, this would cut waste and improve adherence. ... As a result, cost-based value propositions
-
How will capitated budgets affect NHS spending?
If the lead provider delivers the desired services more cost effectively than anticipated, any surplus may be invested in further improving services. ... These changes will see more high tech and high cost drugs being administered in the home supported
-
Wilmington Healthcare
Integrated NHS finances: what do they mean for High Cost Drugs?. ... Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost Drugs.
More from PMHub
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- Amgen reports positive results for Otezla in psoriatic arthritis
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s RSV vaccine approved by FDA for older adults
No results were found
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
- Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
- Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
